Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Atea Pharmaceuticals, Inc. (AVIR)

4.1000 -0.0100 (-0.24%)
At close: 4:00:01 PM EST
4.1000 0.0000 (0.00%)
After hours: 4:00:13 PM EST
Trade AVIR on Coinbase
Chart Range Bar
Loading chart for AVIR
  • Previous Close 4.1100
  • Open 4.2200
  • Bid 3.0300 x 200
  • Ask 4.0900 x 200
  • Day's Range 3.9450 - 4.2400
  • 52 Week Range 2.8700 - 6.4500
  • Volume 330,293
  • Avg. Volume 280,242
  • Market Cap (intraday) 328.839M
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) --
  • EPS (TTM) -2.0900
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 8.50
  • Motley Fool Rating Bearish

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

ateapharma.com

55

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AVIR
14.85%
S&P 500 (^GSPC)
10.17%

1-Year Return

AVIR
26.15%
S&P 500 (^GSPC)
10.25%

3-Year Return

AVIR
30.57%
S&P 500 (^GSPC)
74.66%

5-Year Return

AVIR
65.02%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -32.93M
Profit Margin 0.00%

Q2

FY25

Q3

FY25

Q4

FY25

Q2

FY26

-40M
-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

7.00
8.50 Average
4.1000 Current
10.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/13/2026
Analyst Morgan Stanley
Rating Action Maintains
Rating Equal-Weight
Price Action Raises
Price Target 6 -> 7

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    330.44M

  • Enterprise Value

    111.40M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.62

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -36.72%

  • Return on Equity (ttm)

    -58.14%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -165.29M

  • Diluted EPS (ttm)

    -2.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    219.46M

  • Total Debt/Equity (mrq)

    0.21%

  • Levered Free Cash Flow (ttm)

    -92.83M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

4.1000 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: